Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863311 · ClinicalTrials.gov registry record · Phase 2
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
A Phase 2 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Karie Runcie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT06863311: Recruiting Phase 2 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Karie Runcie.
NCT06863311 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma that is actively recruiting participants, run by Karie Runcie. The registered enrollment target is 70 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06863311, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by Karie Runcie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
Primary Outcome
ORR is defined as the proportion of patients with partial response and complete response per RECIST version 1.1 criteria at any time prior to 6 months
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG XL092
Study Locations (2)
Missouri
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT06863311 shows while recruiting
NCT06863311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT06863311 reports a single indexed study location in Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT06863311 about?
NCT06863311 is a clinical study titled "Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC". The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycle...
What is the current status of trial NCT06863311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2026-03-13. Estimated completion is 2028-12.
What conditions does trial NCT06863311 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma.
What interventions are being tested in trial NCT06863311?
The interventions under investigation include: Nivolumab (DRUG), XL092 (DRUG).
Who is sponsoring clinical trial NCT06863311?
This trial is sponsored by Karie Runcie, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863311 being conducted?
This trial has 2 study locations across Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06863311's enrollment target sits among peer trials
70 25th of 45 higher than 21 of 45 other Clear Cell Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI